These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 21684381)

  • 61. HPV infections and cytologic abnormalities in vaccinated women 21-34 years of age: Results from the baseline phase of the Onclarity trial.
    Wright TC; Parvu V; Stoler MH; Kodsi S; Eckert K; Yanson K; Cooper CK
    Gynecol Oncol; 2019 May; 153(2):259-265. PubMed ID: 30853359
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom.
    Choi YH; Jit M; Gay N; Cox A; Garnett GP; Edmunds WJ
    Vaccine; 2010 May; 28(24):4091-102. PubMed ID: 19909831
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Dose-related Effectiveness of Quadrivalent Human Papillomavirus Vaccine Against Cervical Intraepithelial Neoplasia: A Danish Nationwide Cohort Study.
    Verdoodt F; Dehlendorff C; Kjaer SK
    Clin Infect Dis; 2020 Feb; 70(4):608-614. PubMed ID: 30892587
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain.
    De La Fuente J; Hernandez Aguado JJ; San Martín M; Ramirez Boix P; Cedillo Gómez S; López N
    Hum Vaccin Immunother; 2019; 15(7-8):1949-1961. PubMed ID: 30698488
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Estimates of the timing of reductions in genital warts and high grade cervical intraepithelial neoplasia after onset of human papillomavirus (HPV) vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2013 Aug; 31(37):3899-905. PubMed ID: 23820080
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Human papillomavirus vaccine to prevent cervical intraepithelial neoplasia in Japan: A nationwide case-control study.
    Ikeda S; Ueda Y; Hara M; Yagi A; Kitamura T; Kitamura Y; Konishi H; Kakizoe T; Sekine M; Enomoto T; Sobue T
    Cancer Sci; 2021 Feb; 112(2):839-846. PubMed ID: 33040433
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme.
    Anttila A; Kotaniemi-Talonen L; Leinonen M; Hakama M; Laurila P; Tarkkanen J; Malila N; Nieminen P
    BMJ; 2010 Apr; 340():c1804. PubMed ID: 20423964
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
    Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
    Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland.
    Pollock KG; Kavanagh K; Potts A; Love J; Cuschieri K; Cubie H; Robertson C; Cruickshank M; Palmer TJ; Nicoll S; Donaghy M
    Br J Cancer; 2014 Oct; 111(9):1824-30. PubMed ID: 25180766
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.
    Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LC; Cuzick J; Myers O; Castle PE; Wheeler CM;
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):36-42. PubMed ID: 26518316
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
    Rambout L; Hopkins L; Hutton B; Fergusson D
    CMAJ; 2007 Aug; 177(5):469-79. PubMed ID: 17671238
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy.
    Brotherton JM; Kaldor JM; Garland SM
    Sex Health; 2010 Sep; 7(3):310-9. PubMed ID: 20719220
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
    Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
    Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark.
    Kjaer SK; Breugelmans G; Munk C; Junge J; Watson M; Iftner T
    Int J Cancer; 2008 Oct; 123(8):1864-70. PubMed ID: 18661520
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis.
    Brotherton JM; Budd A; Rompotis C; Bartlett N; Malloy MJ; Andersen RL; Coulter KA; Couvee PW; Steel N; Ward GH; Saville M
    Papillomavirus Res; 2019 Dec; 8():100177. PubMed ID: 31319173
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The impact of human papillomavirus type on colposcopy performance in women offered HPV immunisation in a catch-up vaccine programme: a two-centre observational study.
    Munro A; Gillespie C; Cotton S; Busby-Earle C; Kavanagh K; Cuschieri K; Cubie H; Robertson C; Smart L; Pollock K; Moore C; Palmer T; Cruickshank ME
    BJOG; 2017 Aug; 124(9):1394-1401. PubMed ID: 28102931
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK.
    Cuzick J; Castañón A; Sasieni P
    Br J Cancer; 2010 Mar; 102(5):933-9. PubMed ID: 20104226
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pre-vaccination type-specific HPV prevalence in confirmed cervical high grade lesions in the Māori and non-Māori populations in New Zealand.
    Kang YJ; Lewis H; Smith MA; Simonella L; Neal H; Bromhead C; Canfell K
    BMC Infect Dis; 2015 Aug; 15():365. PubMed ID: 26297490
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Knowledge of Cervical Cancer and Human Papillomavirus among Japanese Women.
    Nakao Y; Sasaki AI; Obara T; Abe S; Furusaki K; Higaki M; Yoshimachi S; Gotou T
    Asian Pac J Cancer Prev; 2020 Dec; 21(12):3527-3532. PubMed ID: 33369448
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012.
    Hariri S; Bennett NM; Niccolai LM; Schafer S; Park IU; Bloch KC; Unger ER; Whitney E; Julian P; Scahill MW; Abdullah N; Levine D; Johnson ML; Steinau M; Markowitz LE;
    Vaccine; 2015 Mar; 33(13):1608-13. PubMed ID: 25681664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.